drugset / Trial / NCT01284959
Different Safety Profile of Risperidone and Paliperidone Extended-release
Phase 4
Completed
34 enrolled
Chonbuk National University Hospital
AstraZeneca · collabJanssen Korea, Ltd., Korea · collabKorea Otsuka Pharmaceutical Co., Ltd. · collabSanofi-Synthelabo · collab
RandomizedParallel-groupDouble-blind
Summary
The main objective of this study was to assess subjective experiences related to secondary negative symptoms and cognitive performance in healthy volunteers in response to multiple doses of paliperidone ER and risperidone in a double-blind, placebo-controlled trial. Adverse events caused by these drugs were also evaluated.
Timeline
- Start
- 2010-06
- Primary completion
- 2010-07
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paliperidone | Unknown | 6 mg | Oral |
| Subject | Risperidone | Other / unclassified | 3 mg | Oral |